Citi Research

Puma Biotechnology (NYSE: PBYI) has nearly tripled in value Wednesday on positive trial data for its lead breast cancer drug, while one analyst said the company is a likely takeover target. After the close Tuesday, the company said a Phase III clinical trial of its neratinib breast cancer drug...

In a report published Friday, Citi Research analyst Jason Bazinet downgraded DIRECTV (NASDAQ: DTV) from Buy to Neutral and raised the price target from $79.00 to $82.00. Bazinet noted that the bull case was based on fundamentals, but sees little upside on current equity values. The analyst...

In a report published Thursday, Citi Research analyst Jason Bazinet downgraded Dish Network (NASDAQ: DISH) from Buy to Neutral and maintained a $61.00 price target as the company's spectrum is fairly valued. Last August, Bazinet commented that Dish Network's spectrum was undervalued by the market...

In a report published Thursday, Citi Research analyst Mark May reiterated a Buy rating on Yahoo! (NASDAQ: YHOO) noting the Buying opportunity on current share valuation. May noted that the 5% pullback in shares following Yahoo's fourth quarter earnings creates a buying opportunity as the current...

In a report published Sunday, Citi Research analyst Jason Gursky initiates coverage on Booz Allen Hamilton Holding Corporation (NYSE: BAH) with a Neutral rating and $19.00 price target. Gursky noted that "Sales are down ~8% over the last 2 years, but margins are up ~300 bps as the company has...

Citi Research analyst Mark May raised the price target on Yahoo! (NASDAQ: YHOO) from $39.00 to $46.00 after re-evaluating the model. May made four adjustments to the model. Citi "1) increased our CY14 opex to better reflect mgmt's 3Q13 commentary; 2) raised our target P/E multiple for Alibaba...